GSK Launches UK Apprenticeship Program
GlaxoSmithKline (GSK) is launching a new program that will create apprenticeships in several areas including manufacturing and R&D at the company’s United Kingdom sites.
GlaxoSmithKline (GSK) is launching a new program that will create apprenticeships in several areas including manufacturing and R&D at the company’s United Kingdom sites. The scheme will commence in August and will offer 40 placements for young people (aged 16–24 years old) in the first intake.
Opportunities will be available in IT, R&D, manufacturing, supply chain management, and artwork design. The apprenticeships will be offered at nine sites: Barnard Castle, GSK House (London), Irvine, Maidenhead, Montrose, Slough, Ulverston, Ware, and Worthing. Depending on the discipline, the roles are expected to last between two and four years. Apprentices may be offered roles within the company at the end of the program.
According to a statement from GSK, the scheme will provide young people with hands-on experience in the life-sciences industry, as well as a base salary and a personalized training plan.
In the statement, John Hayes, the UK’s Skills Minister, said “The government has significantly increased investment in apprenticeships because we know they work for businesses and employees. The unique combination of high-quality training and meaningful work experience they offer helps to build a workforce with the skills our economy needs to grow. I am delighted that GSK are not only hiring new apprentices, but also expanding their program to cover a wide range of new disciplines.”
GSK has several programs in place to attract young talent. In 2011, the company revealed plans to reimburse 100% of uncapped university tuition fees for students recruited under its graduation scheme. This year, the company is also undertaking a ‘Scientists in Sport’ program in partnership with King’s College London (UK), which aims to showcase how science will be used during the upcoming 2012 London Olympic and Paralympic Games and inspire young people to choose scientific careers.
GSK currently employs approximately 15,000 people in the UK.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
